Hikma sells US copies of 3 of the blockbuster drugs on this tracker and has 2 filed or in development. Those brands earned $22.0B in 2025. Of the 70 makers we follow, 17 are lined up to copy more of these drugs.
| Drug | Hikma's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Stelara StarjemzaBiosimilar · Johnson & Johnson · US LOE 2025 | FDA-approved 22 May 2025; launched 6 Nov 2025; interchangeable With Bio-Thera |
7 on sale · 0 approvedof 7 other makers listed | $6.1B |
| Prolia EnobyBiosimilar · Amgen · US LOE 2025 | FDA-approved 26 Sep 2025; launched 19 Jan 2026; interchangeable | 6 on sale · 3 approvedof 10 other makers listed | $4.4B |
| Xgeva XtrenboBiosimilar · Amgen · US LOE 2025 | FDA-approved 26 Sep 2025; launched 19 Jan 2026; interchangeable | 5 on sale · 4 approvedof 10 other makers listed | $2.1B |
| Drug | Hikma's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| JakafiGeneric · Incyte · US LOE 2028 | Filed with the FDA; settled, terms confidential | 0 on sale · 0 approvedof 9 other makers listed | $3.1B |
| VyndaqelGeneric · Pfizer · US LOE 2031 | Filed with the FDA; settled Apr 2026; US entry allowed from 1 Jun 2031 | 0 on sale · 0 approvedof 3 other makers listed, plus unnamed filers | $6.4B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not Hikma's own sales. See the launch tracker →
Each row is a copy Hikma sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Hikma's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Hikma's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: Hikma.